The Role of MiRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 May 2

PMID 32354046

Citations 17

Authors

Anna Kirstein

Thomas E Schmid

Stephanie E Combs

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) is the most common high-grade intracranial tumor in adults. It is characterized by uncontrolled proliferation, diffuse infiltration due to high invasive and migratory capacities, as well as intense resistance to chemo- and radiotherapy. With a five-year survival of less than 3% and an average survival rate of 12 months after diagnosis, GBM has become a focus of current research to urgently develop new therapeutic approaches in order to prolong survival of GBM patients. The methylation status of the promoter region of the O-methylguanine-DNA methyltransferase (MGMT) is nowadays routinely analyzed since a methylated promoter region is beneficial for an effective response to temozolomide-based chemotherapy. Furthermore, several miRNAs were identified regulating MGMT expression, apart from promoter methylation, by degrading MGMT mRNA before protein translation. These miRNAs could be a promising innovative treatment approach to enhance Temozolomide (TMZ) sensitivity in MGMT unmethylated patients and to increase progression-free survival as well as long-term survival. In this review, the relevant miRNAs are systematically reviewed.

Citing Articles

Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.

Jasim S, Ahmed A, Kubaev A, Kyada A, Alshahrani M, Sharma S Med Oncol. 2024; 41(11):265.

PMID: 39400677 DOI: 10.1007/s12032-024-02529-9.

The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer.

Fang Q Cancers (Basel). 2024; 16(2).

PMID: 38254819 PMC: 10814553. DOI: 10.3390/cancers16020331.

Nikolova E, Laleva L, Milev M, Spiriev T, Stoyanov S, Ferdinandov D Noncoding RNA Res. 2023; 9(1):141-152.

PMID: 38035044 PMC: 10686814. DOI: 10.1016/j.ncrna.2023.10.003.

A new prognostic model for glioblastoma multiforme based on coagulation-related genes.

Zhou M, Deng Y, Fu Y, Liang R, Liu Y, Liao Q Transl Cancer Res. 2023; 12(10):2898-2910.

PMID: 37969372 PMC: 10643966. DOI: 10.21037/tcr-23-322.

A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma.

Hasan H, Afzal M, Castresana J, Shahi M Cells. 2023; 12(12).

PMID: 37371047 PMC: 10297163. DOI: 10.3390/cells12121578.

References

Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse M, Back M . Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. J Neurooncol. 2016; 128(1):163-171. DOI: 10.1007/s11060-016-2094-0. View

Ohgaki H, Kleihues P . Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007; 170(5):1445-53. PMC: 1854940. DOI: 10.2353/ajpath.2007.070011. View

Straube C, Kessel K, Zimmer C, Schmidt-Graf F, Schlegel J, Gempt J . A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital Biomarkers. Curr Treat Options Oncol. 2019; 20(9):71. DOI: 10.1007/s11864-019-0673-y. View

Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M . Long-term survival with glioblastoma multiforme. Brain. 2007; 130(Pt 10):2596-606. DOI: 10.1093/brain/awm204. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

Comincini S, Allavena G, Palumbo S, Morini M, Durando F, Angeletti F . microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. Cancer Biol Ther. 2013; 14(7):574-86. PMC: 3742487. DOI: 10.4161/cbt.24597. View

Nabors L, Fink K, Mikkelsen T, Grujicic D, Tarnawski R, Nam D . Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015; 17(5):708-17. PMC: 4482861. DOI: 10.1093/neuonc/nou356. View

Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y . MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 2010; 1359:14-21. DOI: 10.1016/j.brainres.2010.08.074. View

10.

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View

11.

Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J . Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012; 48(10):1532-42. DOI: 10.1016/j.ejca.2011.12.013. View

12.

Hammond S, Bernstein E, Beach D, Hannon G . An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 2000; 404(6775):293-6. DOI: 10.1038/35005107. View

13.

Lee Y, Jeon K, Lee J, Kim S, Kim V . MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002; 21(17):4663-70. PMC: 126204. DOI: 10.1093/emboj/cdf476. View

14.

Zhang J, Stevens M, Bradshaw T . Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2011; 5(1):102-14. DOI: 10.2174/1874467211205010102. View

15.

Belanich M, Randall T, Pastor M, Kibitel J, Alas L, Dolan M . Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol. 1996; 37(6):547-55. DOI: 10.1007/s002800050427. View

16.

Karagkouni D, Paraskevopoulou M, Chatzopoulos S, Vlachos I, Tastsoglou S, Kanellos I . DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. Nucleic Acids Res. 2017; 46(D1):D239-D245. PMC: 5753203. DOI: 10.1093/nar/gkx1141. View

17.

Xia H, He T, Liu C, Cui Y, Song P, Jin X . MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem. 2009; 23(4-6):347-58. DOI: 10.1159/000218181. View

18.

Dungey F, Loser D, Chalmers A . Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys. 2008; 72(4):1188-97. DOI: 10.1016/j.ijrobp.2008.07.031. View

19.

Guo M, Zhang X, Wang G, Sun J, Jiang Z, Khadarian K . miR-603 promotes glioma cell growth via Wnt/β-catenin pathway by inhibiting WIF1 and CTNNBIP1. Cancer Lett. 2015; 360(1):76-86. DOI: 10.1016/j.canlet.2015.02.003. View

20.

Garg T, Bhandari S, Rath G, Goyal A . Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. J Drug Target. 2015; 23(10):865-87. DOI: 10.3109/1061186X.2015.1029930. View